Millennium Management LLC Has $164,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE)

Millennium Management LLC lowered its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 98.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 19,674 shares of the biotechnology company’s stock after selling 1,589,119 shares during the period. Millennium Management LLC’s holdings in bluebird bio were worth $164,000 as of its most recent filing with the SEC.

Separately, Regeneron Pharmaceuticals Inc. acquired a new stake in bluebird bio during the fourth quarter worth about $175,000. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Price Performance

bluebird bio stock opened at $4.97 on Friday. The business has a 50 day simple moving average of $4.53 and a 200 day simple moving average of $5.95. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The company has a market capitalization of $48.67 million, a PE ratio of -0.13 and a beta of 0.27. bluebird bio, Inc. has a one year low of $3.20 and a one year high of $28.60.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BLUE shares. Wall Street Zen assumed coverage on bluebird bio in a research note on Thursday, May 15th. They set a “sell” rating on the stock. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Barclays decreased their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Finally, Wells Fargo & Company lowered their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $44.60.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.